Comparative Pharmacology
Head-to-head clinical analysis: LYSODREN versus MONJUVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYSODREN versus MONJUVI.
LYSODREN vs MONJUVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adrenocorticolytic agent; causes adrenal cortical necrosis and suppresses adrenal steroidogenesis, especially glucocorticoids and mineralocorticoids.
MONJUVI (tafasitamab-cxix) is a humanized Fc-engineered CD19-directed cytolytic monoclonal antibody. It binds to CD19 antigen on the surface of pre-B and mature B lymphocytes, and upon binding, facilitates antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Oral, initial dose 2-6 g/day divided in 3-4 doses, increase gradually to 8-10 g/day. Maximum dose 18 g/day.
3 mg/kg intravenously over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
18-159 days; clinical context: during chronic therapy, steady-state may not be reached for 3-6 months.
Terminal half-life: approximately 17 days (range 11-27 days). This supports a dosing interval of every 2 weeks, as steady state is reached by approximately 70 days.
Primarily renal excretion of metabolites; about 10% as unchanged drug. Biliary/fecal excretion accounts for <5%.
Monjuvi (tafasitamab-cxix) is a monoclonal antibody primarily catabolized into small peptides and amino acids. No specific data on renal or biliary excretion; minimal intact drug excreted in urine or feces. Expected to undergo general protein degradation.
Category C
Category C
Antineoplastic
Antineoplastic